WO2003093346A1 - Multifunctional polyethylene glycol derivatives: preparation and use - Google Patents

Multifunctional polyethylene glycol derivatives: preparation and use Download PDF

Info

Publication number
WO2003093346A1
WO2003093346A1 PCT/EP2003/004620 EP0304620W WO03093346A1 WO 2003093346 A1 WO2003093346 A1 WO 2003093346A1 EP 0304620 W EP0304620 W EP 0304620W WO 03093346 A1 WO03093346 A1 WO 03093346A1
Authority
WO
WIPO (PCT)
Prior art keywords
peg
formula
radical
unit
multipeg
Prior art date
Application number
PCT/EP2003/004620
Other languages
English (en)
French (fr)
Inventor
Gian Maria Bonora
Sara Drioli
Maurizio Ballico
Original Assignee
Universita' Degli Studi Di Trieste
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universita' Degli Studi Di Trieste filed Critical Universita' Degli Studi Di Trieste
Priority to AU2003229769A priority Critical patent/AU2003229769A1/en
Publication of WO2003093346A1 publication Critical patent/WO2003093346A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Definitions

  • the present invention refers to multifunctional polyethylene glycol derivatives (multiPEG), their preparation obtained by assembling PEG units through a polyfunctional linker, and their use.
  • multiPEG multifunctional polyethylene glycol derivatives
  • PEG Polyethylene glycol
  • Polymeric materials based thereon are arousing great interest in view of their application in the biotechnological and pharmacological' fields [Poly(ethylene gly ⁇ ol) Chemistry. Biotechnical and Biomedical Applications, J. Milton Harris Ed., Plenum Press, New York, 1992).
  • the major example of said application is the PEGylation of peptides and proteins (F.M. Veronese, Biomaterials, 22, 405-417, 2001).
  • Recent investigations also concerned the PEGylation of oligonucleotide chains capable of behaving as antisense and antigen (G.M. Bonora et al., Farmaco, 53, 634-637, 1998) or ribozymes for the specific hydrolysis of RNA chains (L Gold, J. Biol. Chem., 270, 13581-13584, 1995).
  • the scarce cell uptake generally exhibited by the charged polar chains of oligonucleotides may be improved by the amphiphilic character of the PEG chains.
  • an increased stability to enzymatic degradation (G.M. Bonora et al. Bioconjugate Chem., 8, 793-797, 1997) and a longer retention time in the blood circulatory system - with an effect that is the higher, the higher is the polymer molecular weight - have been observed. ;
  • anticancer agents such as doxorubicin and taxol
  • antimalarial drugs such as artemisine
  • various enzymatic inhibitors such as doxorubicin and taxol
  • PEG being a synthetic polymer
  • the polydispersity value (M w /M n ) passes from 1.01 in low-molecular-weight samples (3 kDa) to more than 1.2 in the high-molecular- weight ones (>10 kDa).
  • Said polydispersity is a negative feature, which reflects in the conjugate and in its final characteristics.
  • a further basic feature is its use in the so-called "liquid phase synthesis", or synthesis in solution, supported on soluble polymers.
  • Said method is somehow complementary to Merrifield's synthesis on a solid support, except that - like traditional syntheses - it is carried out in solution. It follows that no problems arise due to the reaction environment heterogeneity.
  • the system may be applied to the support of reagents, to their removal from the solution and, obviously, to the transient support of the molecule in the assembling step.
  • the polymers used to this end must satisfy some conditions, e.g. commercial availability, good chemical and mechanical properties, presence of appropriate functional groups for the organic molecules attachment, as well as the required solubilising properties.
  • said polymers should have an as narrow as possible range of molecular weights to avoid the occurrence of different properties with size variation.
  • the polymeric support must not interfere with the envisaged reaction conditions; therefore, it usually consists of hydrocarbon- or ether-type chains.
  • the functionalising capacity of the selected polymer - measured as the number of reactive sites/g polymer - must be as high as possible, compatibly with the solubilising capacity.
  • the soluble polymeric support most widely used so far for the aforesaid purposes is monomethoxy PEG, generally with a m.w. of 5 kDa. Since, as already said, its linear topology gives only one functionalisable reactive group, its capacity is rather limited, i.e. 0.2 mmole/g polymer. With a view to increasing said capacity, which limits the use of PEG, a linear bifunctional PEG, modified by benzylether dendrons, was proposed (M. Benaglia et al, J.Org.Chem., 63, 8628-8629, 1998).
  • PEG-star polymers based on a polyphosphazenic or polyglyceric nucleus where several PEG chains were introduced (N.N. Reed and K.D. Janda, Org. Lett., 2, 1311-1313, 2000).
  • the advantage of said polyethers lies in their high chemical stability and in the good reactivity of the functional groups in the homogeneous phase, with a capacity 4 to
  • polyesters under the trademark Bolt ⁇ rn® from Perstorp and polyesteramides under the trademark Hybrane® from DSM. They generally have a low molecular weight and a very wide and little defined molecular weight distribution (>2); furthermore, their chemical ""stability is limited by the presence in the skeleton of ester and amidic bonds.
  • a very promising class of high-capacity soluble polymeric supports consists of aliphatic dendritic polyethers and of hyperbranched polyethers-polyols. They were recently proposed using 1,2 and 1,3-diol end groups, and were obtained, by convergent synthesis, from the condensation of propylene glycol and methallyl dichloride growing units, or by divergent synthesis starting from a multifunctional core represented by glycerol which binds glycidol growing units (M. Jayaraman and J.M.J. Frechet, J.
  • said multimeric systems - considered vs. the polymers with a comparable molecular weight - must have a defined m.w. range and a higher binding capacity of organic molecules. It is a further aim of the present invention to develop processes for the preparation of said new multimeric systems simple, reproducible and of easy application to an industrial scale. Summary of the invention
  • multiPEG complex-structured multifunctional polyethylene glycol derivatives
  • multifunctional polyethylene glycol derivatives having a complex branched structure of formula (I)
  • a process for the synthesis of multifunctional polyethylene glycol derivatives (multiPEG) having a branched complex structure comprising at least the following steps:
  • multifunctional polyethylene glycol derivatives with the desired size and complex structure and the products " obtained with said process are further objects of the present invention.
  • Jt is a still further object of the present invention to use complex-structured multifunctional polyethylene glycol derivatives (multiPEG) as carriers or stabilisers of pharmacologically or biologically active substances as well as of reagents and catalysts for liquid phase synthesis reactions and as soluble support in synthetic processes.
  • multiPEG complex-structured multifunctional polyethylene glycol derivatives
  • Figure 2 Analytical GPC on HP 1100 - column: PL aquagel-OH 30 8 micron;
  • high-molecular-weight polymers have found extensive application in the biotechnological and pharmaceutical fields as carriers of organic molecules for pharmaco-therapeutic purposes and for organic synthesis.
  • said polymers exhibit some disadvantages, which, in the case of high-molecular-weight PEGs consist in their polydispersity and low binding capacity and, in the case of the conjugation with other polymers, in poor physicochemical properties, such as for example gel formation or poor solubility or extremely complex and expensive synthesis processes.
  • multifunctional polyethylene glycol derivatives having a complex branched structure of formula (I)
  • z-w Z-W m comprise more than one PEG unit assembled through a polyfunctional linker of formula (II)
  • Y and Y are each reactive functional groups, selected out of OH, SH, NH 2 , either free or protected by appropriate protecting groups;
  • Z is a third functional group different from Y or Y' selected out of OH, SH, NH 2 and, when present inside the compounds of formula (I), out of -O-, -S-, -NH-;
  • R and R identical or different, are each a hydrocarbon residue, either cyclic or acyclic, linear or branched, saturated or unsaturated aliphatic, or aromatic, comprising from 1 to 10 carbon atoms;
  • R' can be H or CH 3 ;
  • n can be equal to 0 or 1 , wherein at least one of the two R and R" is present;
  • X' can be a -PEG-X unit
  • X, X', W, W or -Z-W and -Z-W can be a) H b) a -PEG-X unit c) a radical of formula (V) -PEG-Z- (R) n o -PEG-Z-(R") n (V)
  • the PEG unit can be a PEG with a m.w. higher than 500 Da and preferably ranging from 500 to 3000 Da.
  • the protecting group of a functional group of the PEG unit can be any acid- or base-labile group known for the protection of a primary OH functional group, such as for example 4,4-dimethoxytrityl (DMT-CI) or 9-fluorenylmethoxycarbonyl (FmocCI).
  • DMT-CI 4,4-dimethoxytrityl
  • FmocCI 9-fluorenylmethoxycarbonyl
  • Jinker of formula (II) can be any known group for the protection of the OH, SH, NH 2 functional groups, such as for example the aforementioned DMT-CI and FmocCI for the OH group, or benzyloxycarbonyl Z for the NH 2 group, and pyridyl disulphide for the SH group.
  • Multifunctional polyethylene glycol derivatives having a complex structure, formed by the repetition of PEG units with a defined m.w. higher than 500 Da assembled by successive condensation reactions through the linker of formula (II), can be prepared with a synthesis process, described in detail hereinafter, in any case characterized at least by:
  • multiPEG multifunctional polyethylene glycol derivatives
  • multifunctional polyethylene glycol derivatives (multiPEG) with a complex branched structure, characterised by the repetition of PEG units assembled by successive condensation reactions through a linker of formula (II), where Y and Y' are identical or different and Z is an OH group
  • the following steps are envisaged: a) selective monoderivatisation with an appropriate protecting group of the starting PEG unit with a defined m.w. and separation of the same; b) activation of the.residual OH functional group of the monoprotected PEG unit; c) assembling of two monoprotected and activated PEG units through a condensation with a linker of formula (II) having the aforesaid characteristics, with formation of a first multifunctional unit containing two starting PEG units; d) starting from the unit obtained in the preceding step, repetition, if any, of the step of activation of the functional group of the linker of the PEG unit, and of step c) in which the linker may be identical with or different from the starting linker, to obtain the desired multifunctional derivatives (multiPEG) containing several PEG units with a defined molecular weight.
  • a detailed description of the aforesaid process follows: a. Selective monoderivatisation of the starting PEG
  • the process may further proceed according to the strategy just described.
  • the branching structure is modified and the starting PEG unit constitutes the core of the final multiPEG derivative.
  • linkers of formula (II) where Y and Y' are two groups equal to OH and Z is different, being a higher-nucleophilicity reactive group.
  • the steps of the synthesis are described in detail hereinbelow: a) activation of the OH functional groups of the PEG unit; b) introduction into the activated PEG unit of two linkers of formula (II) exhibiting the aforementioned characteristics; c) selective monoderivatisation with an appropriate protecting group of another PEG unit with a defined molecular weight; d) modification of OH groups " of PEG units obtained in step b) or c) with a higher nucleophilic moiety; e) activation of the residual OH functional groups of the PEG units obtained in step b) or c); f) assembling of one or more PEG units obtained in step c) on the multifunctional core obtained in step e); g) deprotection of the functional group of
  • step d) The repetition, if any, of the step of activation of the functional groups of the linkers introduced into the PEG unit as well as of step d) will yield multifunctional derivatives, multiPEGs, with a higher structural complexity.
  • a further synthesis scheme for assembling the polymeric system, object of the present invention, through two different linkers, can be envisaged.
  • the first linker is the same as that used in the 2nd synthesis scheme, while the second is characterised by Y and Y' equal or different from each other and different from Z being Z equal to OH, where one of the two Y or Y' functional groups is temporarily and selectively protected by a protecting group.
  • complex-structured multiPEG derivatives are obtained, wherein the initial PEG unit represents the core as in the previous case, but branching is different.
  • OH in which one of the two Y or Y' functional groups is protected by an appropriate protecting group; d> activation of the OH functional groups of the linkers of the PEG unit obtained in b); ' ", ' e) introduction of the linkers obtained in step c) into the PEG unit obtained in the preceding step; f) selective monoprotection of other PEG units and activation of the residual functional group; g) deprotection of the functional group of the linker and introduction into the unit obtained in e) of monoprotected and activated PEG units obtained in f).
  • the process may further proceed according to the strategy just described.
  • multiPEGs with multiple molecular weights in respect of the molecular weight of the starting PEG unit can be obtained.
  • the molecular weight of the multiPEGs of the present invention may be selected depending on the envisaged use of multiPEG.
  • the use of a different linker in the synthesis may cause a variation in the final product characteristics, i.e. an increase in the intermediate chain length or a variation in chemical functionalities.
  • Example 1 Synthesis of tetra-PEG-pentaol (scheme 1) A) Synthesis of DMT-PEGttnnm-Succinate 1. Synthesis of DMT-PEG(3ooo)- H
  • PEG(3ooo) was co-evaporated twice from anhydrous pyridine in a 250 ml three- necked flask and dried for 30 min by rotary pump. PEG was dissolved in the minimum amount of anhydrous pyridine. Argon was flushed through the side necks by needles. The mixture was added under stirring with 4,4'-dimethoxytrityl chloride (DMT-CI) (powdered; 1.2 equivalents in respect of PEG'S OH groups) and then with 4-dimethylaminopyridine (DMAP) (powdered; 1 equivalent) and triethylamine (TEA) (liquid; 4 equivalents). The mixture was agitated under argon atmosphere, at room temperature, for 4 hrs.
  • DMT-CI 4,4'-dimethoxytrityl chloride
  • DMAP 4-dimethylaminopyridine
  • TAA triethylamine
  • the functionalisation was equal to 62%.
  • DMT-PEG-OH was co-evaporated twice from anhydrous pyridine in a 250 ml three-necked flask and dried for 30 min by rotary pump.
  • the compound was dissolved in the minimum amount of anhydrous pyridine and placed into an ice bath under stirring.
  • the solution was added with succinic anhydride (5 equivalents in respect of the amount of OH still present) and with DMAP (2.5 equivalents), and caused to react under argon atmosphere, at room temperature, overnight, in the dark.
  • succinic anhydride 5 equivalents in respect of the amount of OH still present
  • DMAP 2.5 equivalents
  • the combined DMT-PEG-succinate samples were dissolved in cone. NH 4 OH (50 ml; 30% v/v) in a 250 ml flask and agitated at room temperature for 4 hrs. Ammonia was evaporated to dryness by rotavapor and the residue was taken up with AcCN. The mixture was agitated, at room temperature, for 30 min, the undissolved salt residue was filtered and the AcCN solution was dehydrated with Na 2 SO 4 .
  • the solution was concentrated by rotavapor to approx. 5 ml, and the ice-cooled product was precipitated with anhydrous ether, filtered through a por. 4 Gooch under vacuum, washed with ether, and dried over KOH under vacuum.
  • DMT-PEG-COO-pNO 2 -Phenyl was added portionwise within the span of 2 hrs, while the pH value was maintained at 8 with TEA.
  • the mixture was agitated, at room temperature, for 3 days.
  • the solution turned yellow due to the pNO 2 -phenol released.
  • the product was precipitated in an ice bath with MTBE, washed with /-propanol and ether, and dried over KOH under vacuum. The compound was recrystallised from hot/cold EtOH.
  • PEG(2ooo) was c ⁇ -evaporated twice from anhydrous pyridine in a 250 ml three- necked flask and dried for 30 min by rotary pump. PEG was dissolved in the minimum amount of anhydrous pyridine. Argon was flushed through the side necks by needles. The mixture was added under stirring with 4,4'-dimethoxytrityl chloride, (DMT-CI) (powdered; 1 equivalent in respect of the OH groups present in PEG), 4-dir ⁇ ethyiaminopyridine (DMAP) (powdered; 1 equivalent), and triethylamine (TEA) (liquid; 4 equivalents).
  • DMT-CI 4,4'-dimethoxytrityl chloride
  • DMAP 4-dir ⁇ ethyiaminopyridine
  • TAA triethylamine
  • DMAP succinic anhydride
  • the solution was caused to react under argon atmosphere, at room temperature, overnight, in the dark.
  • the ice-cooled DMT-PEG-succinate was precipitated with anhydrous ether (1 g in approx. 100 ml solvent).
  • the precipitate was ice-cooled under agitation for approx. 30 min and cautiously filtered through a por. 4 Gooch under vacuum.
  • the precipitate was washed a few times with ethyl ether and dried over KOH under vacuum.
  • the resulting product was analysed by ESI-MS and 1 H-NMR.
  • DMT-PEG-succinate Purification of DMT-PEG-succinate was carried out by anion exchange liquid chromatography (IE-LC), using a QAE Sephadex A-50 resin, and a 28 x 1.5 cm column for approx. 0.5 g product.
  • the resin was equilibrated with a 20 mM solution of 1 ,3-diaminopropane in bidistilled H 2 O at pH 9.00. A flow of approx. 1.1 ml/min was maintained.
  • IE-LC anion exchange liquid chromatography
  • the combined DMT-PEG-succinate samples were dissolved in cone. NH 4 OH (50 ml; 30% v/v) in a 250 ml flask and agitated at room temperature for 4 hrs. Ammonia was evaporated to dryness by rotavapor (a 500 ml flask was used to avoid splashes and product loss) and the residue was taken up with AcCN. The mixture was agitated at room temperature of 30 min, the solid left (consisting of salts) was filtered and the AcCN solution was dehydrated with anhydrous Na 2 SO 4 . The solution was concentrated by rotavapor to approx. 5 ml, and the ice-cooled product was precipitated with anhydrous ether, filtered through a por. 4 Gooch under vacuum, washed with ether, and dried over KOH under vacuum. The product was recrystallised from dichlorbmethane/ether.
  • the product was .analysed by 1 H-NMR and ESI-MS, and its functionalisation degree was determined (51.22%).
  • the compound was essentially DMT-PEG-OH containing DMT-PEG-DMT in residual trace amounts.
  • the ice-cooled product was precipitated with anhydrous ethyl ether (1 g in approx. 100 ml solvent), recovered by filtration through a por. 4 Gooch under vacuum, ""Washed with ether, and dried over KOH under vacuum.
  • the product was recrystallised from dichloromethane/ether.
  • the compound analysed by 1 H-NMR and ESI-MS, proved to be DMT-PEG-COO-pNO 2 -Phenyl containing DMT-PEG- DMT in trace amounts.
  • the ice-cooled product was precipitated with anhydrous ethyl ether (1 g in approx. 100 ml solvent), recovered by filtration through a por. 4 Gooch under vacuum, washed with ether, and dried over KOH under vacuum. The product was recrystallised from dichloromethane/ether.
  • PEG( 2 ooo) was co-evaporated twice from anhydrous dichloromethane (DCM) in a 250 ml flask and dried for 30 min by rotary pump. The residue was dissolved in the minimum amount Of anhydrous dichloromethane (DCM), placed into an ice bath and stirred. pN02-phenyl chloroformate (solid, in a 2:1 ratio in respect of the OH groups present in PEG) and triethylamine (TEA) (in a 1 :1 ratio in respect of chloroformate) were added. The ice bath was removed. The solution pH was initially controlled and brought to 8 with TEA. The product was caused to react under agitation, at room temperature, for 24 hrs.
  • DCM anhydrous dichloromethane
  • pN02-phenyl chloroformate solid, in a 2:1 ratio in respect of the OH groups present in PEG
  • TEA triethylamine
  • the residue was dissolved in the minimum amount of anhydrous dichloromethane (DCM) and added with 2-amino-1 ,3-propanediol (solid, in a 3:1 ratio in respect of pNO 2 -phenyl carbonate groups present in the PEG derivative).
  • DCM anhydrous dichloromethane
  • 2-amino-1 ,3-propanediol solid, in a 3:1 ratio in respect of pNO 2 -phenyl carbonate groups present in the PEG derivative.
  • PEG (2 ooo ) -tetraol was co-evaporated twice from anhydrous dichloromethane in a 250 ml flask and dried for 30 min by rotary pump. The residue was dissolved in a mixture of anhydrous solvents - DCM, acetonitrile and pyridine (in a 3:2:1 ratio) - which was added with N,N'-disuccinimidyl carbonate (solid, in a 3:1 ratio in respect of the OH groups present in PEG). The product was caused to react under agitation, at room temperature, for 18 hrs. The ice-cooled product was precipitated with anhydrous ethyl ether (1 g in approx.
  • the ice-cooled product was precipitated with anhydrous ethyl ether (100 ml), recovered by filtration through a por. 3 Gooch under vacuum, washed with ether, and dried over KOH under vacuum.
  • Tetra-Hydroxy-(PEG2ooo)5 obtained in step J) was co-evaporated twice from anhydrous dichloromethane in a 250 ml flask and dried for 30 min by rotary pump. The residue was dissolved in a mixture of anhydrous solvents - DCM, acetonitrile and pyridine (in a' 3:2:1 ratio) - which was added with N,N'-disuccinimidyl carbonate (solid, in a 3:1 ratio in respect of the OH groups present in PEG). The product was caused to react under agitation, at room temperature, for 18 hrs.
  • the ice-cooled product was precipitated with anhydrous ethyl ether (100 ml), recovered by filtration through a por. 3 Gooch under vacuum, washed with ether, and dried over KOH under vacuum. The product was recrystallised from dichloromethane/ether and then analysed by 1 H-NMR.
  • Tetra-OSu-(PEG 2 ooo)5 was co-evaporated twice from anhydrous dichloromethane (DCM) in a 250 ml flask and dried for 30 min by rotary pump. The residue was dissolved in anhydrous dichloromethane, and the solution was added with 2- amino-1 ,3-propanediol (solid, in a 3:1 ratio in respect of the OSu groups present in
  • the product was caused to react under agitation, at room temperature, for
  • Example 3 Synthesis of penta-PEG-dodecaol (scheme 3) The synthesis of multiPEG, containing 5 PEG units and 12 OH functional groups, denominated penta-PEG-dodecaol, was substantially identical with that described in Example 2, steps A, B, C, D, F, G, H, with the exception of step E.
  • the aqueous phase was basified to pH 9 with a 4M NaOH solution and extracted with AcOEt (4 x 30ml).
  • the organic phase was dried over anhydrous Na 2 SO 4 , and the solvent was elimihated by rotary evaporator.
  • PEG (2 ooo)-tetra-OSu was co-evaporated from anhydrous dichloromethane in a 250 ml flask and dried for 30 min by rotary pump. The residue was dissolved in anhydrous dichloromethane (DCM) and the solution was added, under magnetic stirring, with N-BOC-1 ,3-diamino-2-propanol (in a 3:1 ratio in respect of the OSu groups present in PEG). The product was caused to react under stirring, at room temperature, for 18 hrs. The ice-cooled product was precipitated with anhydrous ethyl ether, recovered by filtration through a por. 4 Gooch under vacuum, washed with ether, recrystallised from dichloromethane/ether, and dried over KOH under vacuum.
  • DCM anhydrous dichloromethane
  • the product was characterised by 1 H-NMR and ESI-MS.
  • PEG (2 ooo ) -tetra-amino-tetraol was co-evaporated from anhydrous dichloromethane in a 250 ml flask and dried for 30 min by rotary pump. The residue was dissolved in anhydrous dichloromethane (DCM). The pH value of the solution, which was acid due to the presence of TFA in trace amounts, was adjusted to pH 9 with TEA.
  • the ice-cooled product was precipitated with anhydrous ethyl ether (100 ml), recovered by filtration through a por. 4 Gooch under vacuum, washed with ether, recrystallised from , dichloromethane/ether, and dried over KOH under vacuum.
  • the ice-cooled product was precipitated with anhydrous ethyl ether, recovered by filtration through a por. 4 Gooch under vacuum, and washed with ether. "The DMT recovery procedure was repeated a second time under the conditions described above.
  • Branched tetra-hydroxy-(PEG2ooo)s -tetra-OSu was co-evaporated from anhydrous dichloromethane in a 250 ml flask and dried for 30 min by rotary pump. The residue was dissolved in anhydrous dichloromethane (DCM) and the resulting solution was added with 2-amino-1 ,3-propanediol (in a 3:1 ratio in respect of the OSu groups present in PEG). The product was caused to react under agitation, at room temperature, for 18 hrs.
  • DCM hydrous dichloromethane
  • the ice-cooled product was precipitated with anhydrous ethyl ether, recovered by filtration through a por. 4 Gooch under vacuum, washed with ether, dried over KOH under vacuum, and recrystallised from dichloromethane/ether.
  • the product was analysed by 1 H-NMR and GPC (Fig.1-C; Fig. 2-C).
  • multifunctional PEG derivatives is based on their capacity of binding organic molecules either reagents and catalysts or with a biological and pharmacological activity to residual functional groups of PEG units and of linkers. Therefore, they can be used in supported synthesis processes of biopolymers and complex molecules, both free and PEG-conjugated; syntheses of supported reactive agents; syntheses of supported catalytic systems operating in the homogeneous phase and recyclable and as soluble support in synthetic processes; as carriers and solubilisers of drugs, biologically active molecules such as diagnostic markers, antigens and antibodies, sequences of DNA, and contrast means; in vivo stabilisation of biologically active - natural and synthetic - molecules.
  • multifunctional PEG derivatives may be used either in the free state or conjugated with the aforementioned molecules in compositions with known or new pharmaceutically acceptable diluents and excipients, suitable for the selected purposes and ways of administration.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Polyethers (AREA)
  • Medicinal Preparation (AREA)
PCT/EP2003/004620 2002-05-06 2003-05-02 Multifunctional polyethylene glycol derivatives: preparation and use WO2003093346A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003229769A AU2003229769A1 (en) 2002-05-06 2003-05-02 Multifunctional polyethylene glycol derivatives: preparation and use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2002A000951 2002-05-06
IT2002MI000951A ITMI20020951A1 (it) 2002-05-06 2002-05-06 Derivati multifunzionali del polietilenglicole loro preparazione ed impiego

Publications (1)

Publication Number Publication Date
WO2003093346A1 true WO2003093346A1 (en) 2003-11-13

Family

ID=11449835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/004620 WO2003093346A1 (en) 2002-05-06 2003-05-02 Multifunctional polyethylene glycol derivatives: preparation and use

Country Status (3)

Country Link
AU (1) AU2003229769A1 (it)
IT (1) ITMI20020951A1 (it)
WO (1) WO2003093346A1 (it)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006018429A1 (en) * 2004-08-16 2006-02-23 Novo Nordisk A/S Multimers of peptides
WO2007062610A3 (es) * 2005-11-30 2007-09-20 Ct Ingenieria Genetica Biotech Dendrímero con peg de cuatro ramas para la conjugación a proteínas y péptidos
EP1955712A1 (en) * 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
EP2073820A2 (en) * 2006-09-15 2009-07-01 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
US11725073B2 (en) 2020-12-29 2023-08-15 Hongene Biotech Corporation Compositions and methods for liquid phase oligonucleotide synthesis
US11851454B2 (en) 2021-12-30 2023-12-26 Hongene Biotech Corporation Compositions and methods for liquid phase oligonucleotide synthesis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011924A1 (en) * 1993-10-27 1995-05-04 Enzon, Inc. Non-antigenic branched polymer conjugates
WO1996021469A1 (en) * 1995-01-10 1996-07-18 Shearwater Polymers, Inc. Multi-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
WO1999029759A1 (en) * 1997-12-12 1999-06-17 Macromed, Inc. Heterofunctionalized star-shaped poly(ethylene glycols) for protein modification

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011924A1 (en) * 1993-10-27 1995-05-04 Enzon, Inc. Non-antigenic branched polymer conjugates
WO1996021469A1 (en) * 1995-01-10 1996-07-18 Shearwater Polymers, Inc. Multi-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
WO1999029759A1 (en) * 1997-12-12 1999-06-17 Macromed, Inc. Heterofunctionalized star-shaped poly(ethylene glycols) for protein modification
US6046305A (en) * 1997-12-12 2000-04-04 Macromed, Inc. Heterofunctionalized star-shaped poly(ethylene gycols) for protein modification

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006018429A1 (en) * 2004-08-16 2006-02-23 Novo Nordisk A/S Multimers of peptides
WO2007062610A3 (es) * 2005-11-30 2007-09-20 Ct Ingenieria Genetica Biotech Dendrímero con peg de cuatro ramas para la conjugación a proteínas y péptidos
US8703893B2 (en) 2005-11-30 2014-04-22 Centro De Ingenienia Genetica Y Biotecnologia Four branched dendrimer-PEG for conjugation to proteins and peptides
EP2073820A2 (en) * 2006-09-15 2009-07-01 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
EP2073820A4 (en) * 2006-09-15 2014-07-16 Belrose Pharma Inc TARGETED POLYMER PRODRUGS WITH MULTIFUNCTIONAL CONNECTORS
EP1955712A1 (en) * 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
WO2008096012A2 (en) * 2007-02-09 2008-08-14 Scil Proteins Gmbh Multimeric conjugate
WO2008096012A3 (en) * 2007-02-09 2009-08-20 Scil Proteins Gmbh Multimeric conjugate
JP2010519182A (ja) * 2007-02-09 2010-06-03 シル プロテインズ ゲーエムベーハー 多量体接合体
US8426357B2 (en) 2007-02-09 2013-04-23 Celares Gmbh Multimeric conjugate
US11725073B2 (en) 2020-12-29 2023-08-15 Hongene Biotech Corporation Compositions and methods for liquid phase oligonucleotide synthesis
US11851454B2 (en) 2021-12-30 2023-12-26 Hongene Biotech Corporation Compositions and methods for liquid phase oligonucleotide synthesis

Also Published As

Publication number Publication date
ITMI20020951A1 (it) 2003-11-06
ITMI20020951A0 (it) 2002-05-06
AU2003229769A1 (en) 2003-11-17

Similar Documents

Publication Publication Date Title
EP2576655B1 (en) Membrane enhanced polymer synthesis
KR100807141B1 (ko) 고분자량 비펩티드성 중합체 유도체의 합성
Pasut et al. PEG-epirubicin conjugates with high drug loading
JP5825507B2 (ja) 分岐型ヘテロポリエチレングリコール
US20020091288A1 (en) Discrete-length polyethylene glycols
Pan et al. Studies on PEGylated and drug-loaded PAMAM dendrimers
WO2004083259A2 (en) Activated forms of water-soluble polymers
JP2003511422A (ja) ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
US20060204472A1 (en) Multifunctional dendrimers and hyperbranched polymers as drug and gene delivery systems
MXPA04003340A (es) Polimeros acuosolubles terminados en tioester y metodos de modificar con estos, el n-terminus de un polipeptido.
WO2001045796A2 (en) Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol)
CA2618701A1 (en) Methods of preparing polymers having terminal amine groups
EP1479711A1 (en) Multidrop tree branching functional polyethylene glycol, the preparation method and the use of it
WO2003093346A1 (en) Multifunctional polyethylene glycol derivatives: preparation and use
KR100967833B1 (ko) 고순도의 폴리에틸렌글리콜 알데하이드 유도체의 제조방법
Sedlák Recent advances in chemistry and applications of substituted poly (ethylene glycol) s
JP5105166B2 (ja) ポリエーテルの製造方法
WO2006124205A2 (en) Hydrophilic polymers with pendant functional groups and method thereof
Ballico et al. MultiPEGs: High Molecular Weight Multifunctional Poly (ethylene glycol) s Assembled by a Dendrimer‐Like Approach
JP2008174755A (ja) ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
Brunius et al. Grafting of ω‐Functionalized PVP Oligomers onto Dextran: A Novel Route to Biodegradable and Biocompatible Polymers
Pechar et al. Poly (ethylene glycol)-based polymer carrier of doxorubicin degradable by both enzymatic and chemical hydrolyses
Anjaly et al. Multifunctional polyether grafted dendritic solid supports: Novel class of solvent like high loading hybrid supports for solid phase organic synthesis
Drioli et al. New syntheses of branched, multifunctional high-molecular weight poly (ethylene glycol) s or (MultiPEG) s
JP2012158759A (ja) ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP